

# Appendix

## Reconciliation of Non-GAAP Measures

	2011		2010		2009		2008		2007	
	Earnings From Continuing Operations (\$ millions)	EPS	Earnings From Continuing Operations (\$ millions)	EPS	Earnings From Continuing Operations (\$ millions)	EPS	Earnings From Continuing Operations (\$ millions)	EPS	Earnings From Continuing Operations (\$ millions)	EPS
<b>As reported under GAAP</b>	\$4,728	\$3.01	\$4,626	\$2.96	\$5,746	\$3.69	\$4,734	\$3.03	\$3,606	\$2.31
Acquired in-process R&D	\$673	\$0.43	\$313	\$0.20	\$170	\$0.11	\$76	\$0.05		
Reversal of contingent liability / Gain on the conclusion of the TAP joint venture					(\$505)	(\$0.33)	(\$94)	(\$0.06)		
Venezuela devaluation – balance sheet impact			\$115	\$0.07						
Asset (gains) impairments	\$76	\$0.05					(\$49)	(\$0.03)	\$60	\$0.04
Spin-off, acquisition-related costs and restructuring	\$763	\$0.48	\$1,035	\$0.67	\$508	\$0.32	\$366	\$0.23	\$596	\$0.38
One month lag	\$137	\$0.09								
Health care reform – tax asset impact			\$60	\$0.04						
Litigation	\$1,534	\$0.97	\$106	\$0.07	(\$114)	(\$0.07)	\$183	\$0.12	\$92	\$0.06
Product recall/withdrawal costs			\$88	\$0.06						
Impairment of sibutramine intangible asset			\$158	\$0.10						
Taxes	(\$580)	(\$0.37)					(\$30)	(\$0.02)		
BSX investment									\$75	\$0.05
<b>Excluding specified items</b>	<b>\$7,331</b>	<b>\$4.66</b>	<b>\$6,501</b>	<b>\$4.17</b>	<b>\$5,805</b>	<b>\$3.72</b>	<b>\$5,186</b>	<b>\$3.32</b>	<b>\$4,429</b>	<b>\$2.84</b>